Evidence map›Paper›PMID 35118625›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Generation and Characterization of Single-Cycle Infectious Canine Influenza A Virus (sciCIV) and Its Use as Vaccine Platform.

Aitor Nogales, Kevin Chiem, Michael Breen, Marta L DeDiego, Colin R Parrish, Luis Martínez-Sobrido

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Aitor NogalesCentro de Investigación en Sanidad Animal (CISA), INIA-CSIC, Madrid, Spain. nogales.aitor@inia.es.
Kevin ChiemDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Michael BreenDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Marta L DeDiegoDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Colin R ParrishDepartment of Microbiology and Immunology, College of Veterinary Medicine, Baker Institute for Animal Health, Cornell University, Ithaca, NY, USA.
Luis Martínez-SobridoDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA. lmartinez@txbiomed.org.
University of Rochester Medical Center · USConsejo Superior de Investigaciones Científicas · ESCornell University · USTexas Biomedical Research Institute · US

Funding

NIAID NIH HHS HHSN272201400005C
6 · The paper itself

Abstract

Influenza A viruses (IAVs) infect a broad range of hosts, including multiple avian and mammalian species. The frequent emergence of novel IAV strains in different hosts, including in humans, results in the need for vigilance and ongoing development of new approaches to fighting or prevent those infections. Canine influenza is a contagious respiratory disease in dogs caused by two subtypes of IAV, the equine-origin H3N8 canine influenza virus (CIV), and the avian-origin H3N2 CIV. A novel approach to influenza vaccination involves single-cycle infectious influenza A viruses (sciIAVs), which are defective for an essential viral gene. They are propagated in complementing cell lines which provide the missing gene in trans. As sciIAV cannot complete their replication cycle in regular cells they are limited to a single round of viral replication. Because of their safety profile and ability to express foreign antigens inside infected cells, sciIAVs have served both as live-attenuated vaccines and as vaccine vectors for the expression of heterologous antigens. Here, we describe experimental procedures for the generation of a single-cycle infectious CIV (sciCIV), where the viral hemagglutinin (HA) gene was exchanged for the gene for green fluorescent protein (GFP). Complementation of the viral HA protein is provided in trans by stable HA-expressing cell lines. Methods for the in vitro characterization of HA deficient but GFP-expressing sciCIV (sciCIV ΔHA/GFP) are described, as well as its use as a potential vaccine.

Indexed as

Influenza A virusInfluenza A Virus, H3N8 SubtypeInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsDogsHemagglutinin Glycoproteins, Influenza VirusHorsesInfluenza A Virus, H3N2 SubtypeMadin Darby Canine Kidney CellsMammalsVaccines, AttenuatedHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesVaccines, AttenuatedCanine influenza virusGreen fluorescent proteinHumoral responseInfluenza HA-expressing MDCK cells (MDCK-HA)Influenza vaccineReporter geneReporter virusReverse geneticsSingle-cycle infectious influenza A virusSingle-cycle influenza virusViral vectors

Identifiers

PMID35118625
OpenAlexW4210641840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.